Table 3

Univariate hazard ratios and C-statistic values for lymphocyte count and other prognostic variables

Time to treatment
Overall survival
n (events)C-statistic (SE)HR (95% CI)Difference in time to treatment, Pn (events)C-statistic (SE)HR (95% CI)Difference in survival, P
B-cell count ≥ 11 vs < 11 × 109/L 456 (51) 0.64 (0.04) 3.02 (1.74-5.23) <.001 459 (42) 0.60 (0.05) 2.36 (1.28-4.36) .01 
ALC ≥ 12 vs < 12 × 109/L 456 (51) 0.62 (0.04) 2.28 (1.31-3.97) .003 459 (42) 0.56 (0.04) 1.62 (0.89-2.99) .12 
CD38 435 (48) 0.64 (0.04) 3.21 (1.82-5.70) <.001 438 (37) 0.56 (0.04) 2.17 (1.10-4.25) .03 
ZAP-70 275 (22) 0.76 (0.05) 5.82 (2.48-13.66) <.001 278 (9) 0.51 (0.09) 2.77 (0.74-10.37) .14 
IGHV (unmutated) 274 (35) 0.72 (0.04) 6.25 (3.03-12.5) <.001 277 (17) 0.62 (0.07) 2.86 (1.10-7.69) .03 
FISH 297 (34) 0.58 (0.04) 3.48 (1.51-8.01) .01 299 (15) 0.59 (0.08) 4.47 (1.52-13.12) .01 
    Favorable (normal, 13q−, +12) 
    Unfavorable (17p−, 11q−) 
Time to treatment
Overall survival
n (events)C-statistic (SE)HR (95% CI)Difference in time to treatment, Pn (events)C-statistic (SE)HR (95% CI)Difference in survival, P
B-cell count ≥ 11 vs < 11 × 109/L 456 (51) 0.64 (0.04) 3.02 (1.74-5.23) <.001 459 (42) 0.60 (0.05) 2.36 (1.28-4.36) .01 
ALC ≥ 12 vs < 12 × 109/L 456 (51) 0.62 (0.04) 2.28 (1.31-3.97) .003 459 (42) 0.56 (0.04) 1.62 (0.89-2.99) .12 
CD38 435 (48) 0.64 (0.04) 3.21 (1.82-5.70) <.001 438 (37) 0.56 (0.04) 2.17 (1.10-4.25) .03 
ZAP-70 275 (22) 0.76 (0.05) 5.82 (2.48-13.66) <.001 278 (9) 0.51 (0.09) 2.77 (0.74-10.37) .14 
IGHV (unmutated) 274 (35) 0.72 (0.04) 6.25 (3.03-12.5) <.001 277 (17) 0.62 (0.07) 2.86 (1.10-7.69) .03 
FISH 297 (34) 0.58 (0.04) 3.48 (1.51-8.01) .01 299 (15) 0.59 (0.08) 4.47 (1.52-13.12) .01 
    Favorable (normal, 13q−, +12) 
    Unfavorable (17p−, 11q−) 
Close Modal

or Create an Account

Close Modal
Close Modal